Full Breakdown
Smith & Nephew–Johnson & Johnson Orthopaedics Merger Talks Collapse
By Drooid · · How we work
Core Event
On October 23, Smith & Nephew (SN.L) and Johnson & Johnson (JNJ.N) ended advanced merger negotiations for J&J’s orthopaedics division after failing to agree on the leadership of the combined entity. Smith & Nephew insisted that its current chief executive, Deepak Nath, remain CEO, while J&J preferred former Smith & Nephew CEO Namal Nawana—now president of J&J’s DePuy Synthes orthopaedics unit—to head the merged business. The dispute caused J&J’s interest to cool and the talks collapsed weeks before a planned mid-October announcement.
Background & Context
The proposed transaction, valued at roughly $34 billion, would have given J&J shareholders a 50.1 % stake in the combined company. J&J’s orthopaedics operation was valued at up to $22 billion, nearly double Smith & Nephew’s market capitalisation of about $12.6 billion. The deal also followed J&J’s October-last-year announcement to spin off its orthopaedics business as a standalone company named DePuy Synthes, with a target separation in mid-2027.
Data & Statistics
- Smith & Nephew’s net debt stood at $3.02 billion as of June 27, 2026, a figure more than three times lower than the $10 billion debt financing the merger would have required. [Thedeepdive]
- The proposed borrowing represented roughly 12.5 times Smith & Nephew’s standalone annual free-cash-flow forecast of $800 million for the full year. [Thedeepdive]
- Smith & Nephew reported a net-debt-to-adjusted-EBITDA ratio of 1.8 times and free cash flow of $231 million for the first half of 2026, down from $244 million a year earlier. [Thedeepdive]
Official Statements & Responses
Both companies declined to comment on the reported breakdown of talks. [Reuters]
J&J CEO Joaquin Duato said on October 13 that the company was leaning toward spinning off DePuy Synthes as a standalone entity, with the separation targeted for mid-2027. [Thedeepdive]
Verbatim Quotes
- “The combination would have created a rich portfolio across knee and hip implants, while filling in musculoskeletal gaps in both parties’ offering,” — John West, global head of analysis at Mergermarket — John West, global head of analysis at Mergermarket, on the strategic fit of the proposed combination.